Generalized Myasthenia Gravis Drug Receives EU Approval Generalized Myasthenia Gravis Drug Receives EU Approval

Approved in the US last year, efgartigimod (Vyvgart) is a first-in-class targeted therapy for patients with generalized myasthenia gravis who test positive for the antiacetylcholine receptor antibody.International Approvals
Source: Medscape Neurology and Neurosurgery Headlines - Category: Neurology Tags: Neurology & Neurosurgery News Alert Source Type: news